BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16685406)

  • 1. Expression of thioredoxin and thioredoxin-binding protein-2 in the liver of patients with chronic hepatitis C as a predictor of response to interferon therapy.
    Hamano K; Seo Y; Kato H; Kato M; Yano Y; Ninomiya T; Kasuga M
    Int J Mol Med; 2006 Jun; 17(6):989-95. PubMed ID: 16685406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of thioredoxin and thioredoxin-binding protein-2 in endometriosis.
    Seo SK; Yang HI; Lee KE; Kim HY; Cho S; Choi YS; Lee BS
    Hum Reprod; 2010 May; 25(5):1251-8. PubMed ID: 20172870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatment.
    Carrera G; Paternain JL; Carrere N; Folch J; Courtade-Saïdi M; Orfila C; Vinel JP; Alric L; Pipy B
    Am J Gastroenterol; 2003 May; 98(5):1142-9. PubMed ID: 12809840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.
    Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E
    J Pathol; 2007 Nov; 213(3):347-55. PubMed ID: 17940994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients.
    Abbate I; Romano M; Longo R; Cappiello G; Lo Iacono O; Di Marco V; Paparella C; Spano A; Capobianchi MR
    J Med Virol; 2003 Aug; 70(4):581-7. PubMed ID: 12794720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
    Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
    Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
    P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection.
    Sumida Y; Nakashima T; Yoh T; Nakajima Y; Ishikawa H; Mitsuyoshi H; Sakamoto Y; Okanoue T; Kashima K; Nakamura H; Yodoi J
    J Hepatol; 2000 Oct; 33(4):616-22. PubMed ID: 11059866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.
    Mirandola S; Realdon S; Iqbal J; Gerotto M; Dal Pero F; Bortoletto G; Marcolongo M; Vario A; Datz C; Hussain MM; Alberti A
    Gastroenterology; 2006 May; 130(6):1661-9. PubMed ID: 16697730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease.
    Roulot D; Durand H; Coste T; Rautureau J; Strosberg AD; Benarous R; Marullo S
    Hepatology; 1995 Feb; 21(2):298-304. PubMed ID: 7843697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
    Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
    Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
    Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
    Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
    Pellicano R; Puglisi G; Ciancio A; Balzola F; Saracco G; Ciccone G; Baldi I; Abate ML; Smedile A; Rizzetto M
    J Med Virol; 2008 Apr; 80(4):628-31. PubMed ID: 18297716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
    Fujita N; Horiike S; Sugimoto R; Tanaka H; Iwasa M; Kobayashi Y; Hasegawa K; Ma N; Kawanishi S; Adachi Y; Kaito M
    Free Radic Biol Med; 2007 Feb; 42(3):353-62. PubMed ID: 17210448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.